Innovent Biologics (HKSE:01801) Days Payable

: 99.25 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

Innovent Biologics's average Accounts Payable for the six months ended in Jun. 2023 was HK$300 Mil. Innovent Biologics's Cost of Goods Sold for the six months ended in Jun. 2023 was HK$552 Mil. Hence, Innovent Biologics's Days Payable for the six months ended in Jun. 2023 was 99.25.

The historical rank and industry rank for Innovent Biologics's Days Payable or its related term are showing as below:

HKSE:01801' s Days Payable Range Over the Past 10 Years
Min: 94 Med: 109.19 Max: 187.05
Current: 98.66

During the past 8 years, Innovent Biologics's highest Days Payable was 187.05. The lowest was 94.00. And the median was 109.19.

HKSE:01801's Days Payable is ranked worse than
59.66% of 714 companies
in the Biotechnology industry
Industry Median: 151.205 vs HKSE:01801: 98.66

Innovent Biologics's Days Payable increased from Jun. 2022 (85.17) to Jun. 2023 (99.25). It may suggest that Innovent Biologics delayed paying its suppliers.

Innovent Biologics Days Payable Historical Data

The historical data trend for Innovent Biologics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

187.05

94.00

112.61

105.76

113.23

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial										148.26	85.17	113.94	99.25	85.08

Competitive Comparison

For the Biotechnology subindustry, Innovent Biologics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics Days Payable Distribution

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Days Payable distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Days Payable falls into.

Innovent Biologics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Innovent Biologics's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (238.832	+	363.627)	/	2 )	/	1039.651	*	365
=	301.2295					/	1039.651	*	365
=	105.76

Innovent Biologics's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (363.627	+	236.708)	/	2 )	/	551.938	*	365 / 2
=	300.1675					/	551.938	*	365 / 2
=	99.25

Innovent Biologics Days Payable Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (HKSE:01801) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines